Ebola virus disease – Guinea
The Pharma Data
JUNE 18, 2021
On 14 February 2021, the Ministry of Health (MoH) of Guinea informed WHO of a cluster of Ebola Virus. Source link.
2021 Disease Virus 
Current insights and molecular docking studies of HIV?1 reverse transcriptase inhibitors
Chemical Biology and Drug Design
OCTOBER 10, 2023
Abstract Human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome (AIDS), a lethal disease that is prevalent worldwide. million people worldwide were living with HIV in 2021. Molecular insights of HIV Reverse transcriptase and it's inhibitors.
FDA Approval 
100
100 Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Improved prime editing system makes gene-sized edits in human cells at therapeutic levels
Broad Institute
JUNE 10, 2024
The advance, from the lab of Broad core institute member David Liu , could one day help researchers develop a single gene therapy for diseases such as cystic fibrosis that are caused by one of hundreds or thousands of different mutations in a gene.
DNA 144
144 
Moderna to Build mRNA Vaccine Portfolio Following COVID-19 Success | 2021-01-11
The Pharma Data
JANUARY 11, 2021
Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. billion expected from signed advance purchase agreements for fiscal 2021, Bancel said in a Monday call with investors. 18, 2020 ). Martin Berman-Gorvine.
Vaccine 52
52 
As new cases surge, Kaiser Permanente extends COVID-19 cost waiver through at least March 31, 2021
The Pharma Data
DECEMBER 21, 2020
Kaiser Permanente has announced that it will extend its waiver for most member out-of-pocket costs for inpatient and outpatient services related to the treatment of COVID-19 through at least March 31, 2021 , or as long as the ongoing public health emergency lasts. OAKLAND, Calif. ,
Virus 52
52 
COVID-19 nasal vaccine candidate effective at preventing disease transmission
The Pharma Data
SEPTEMBER 30, 2021
That’s how easy it’s for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. As prior work with other respiratory pathogens like influenza has shown, sterilizing immunity to virus re-infection requires adaptive immune responses within the tract and therefore the lung. Breathe in, exhale. doi: 10.1016/j.isci.2021.103037.
Vaccine 52
52 
Biden COVID Advisor Says Poor Preparation, Changing Virus Could Slow Vaccine Effort
The Pharma Data
JANUARY 21, 2021
21, 2021 — U.S. President Joe Biden has promised to re-energize the nation’s response to COVID-19, but one of his top pandemic advisors says that effort could be hamstrung by both the virus and the failings of the previous administration. © 2021 HealthDay. Posted: January 2021. THURSDAY, Jan. Source link.
Vaccine 52
52 
Memo Therapeutics AG’s Antibody Against SARS-CoV-2 Demonstrates Potent Therapeutic and Prophylactic Activity in Advanced COVID-19 Disease Model
The Pharma Data
DECEMBER 2, 2020
MTX-COVAB was also found to have virus neutralizing potency (IC50= 40pM), which is comparable or better to that of the leading antibody therapies in development, and cross-neutralizes all clinically relevant virus mutants. The company’s current pipeline features programs in infectious diseases and immuno-oncology.
Disease 52
52 
Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
The Pharma Data
MARCH 8, 2021
The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.
Trials 69
69 
Oyagen, Inc. Publishes Study On Its OYA1 As A “Highly Effective” Experimental Drug Candidate For Treating Infections By The Ebola Virus
The Pharma Data
JANUARY 6, 2021
7, 2021 /PRNewswire/ — OyaGen, Inc. A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ ’ (2021) Viruses 13:52 [link]. ROCHESTER, N.Y. , Bennett et al., About OYA1. OYA1 (a.k.a. HHSN272201800013C (S.Y.,
Virus 40
40 
Advances in the Battle Against Autoimmune Disease
The Pharma Data
DECEMBER 15, 2020
A healthy immune system defends the body against disease and other conditions. Autoimmune disease impacts different parts of the body, weakening functionality. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. It may be life-threatening.
Disease 52
52 
Brazilian Coronavirus Variant Found in Minnesota
The Pharma Data
JANUARY 26, 2021
26, 2021 — The first known U.S. “We know that even as we work hard to defeat COVID-19, the virus continues to evolve as all viruses do,” Minnesota Health Commissioner Jan Malcolm said in a statement. Centers for Disease Control and Prevention. © 2021 HealthDay. Posted: January 2021. Professional.
Virus 52
52 
People’s ‘Microbiomes’ Might Influence COVID-19 Severity: Study
The Pharma Data
JANUARY 13, 2021
13, 2021 — The bacteria in your gut may play a role in the severity of COVID-19 infection and the strength of your immune system response, a new study suggests. “Restoration of the missing beneficial bacteria might boost our immunity against SARS-CoV2 virus and hasten recovery from the disease,” she said.
Virus 52
52 
Roche signs definitive share purchase agreement with long-term partner TIB.
The Pharma Data
SEPTEMBER 8, 2021
Roche to acquire the TIB Molbiol Group with the expectation to close in fourth quarter of 2021. TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. The majority of assays are used to test for infectious diseases.
Virus 52
52 
Answering Your Qs on the New COVID Vaccines
The Pharma Data
JANUARY 11, 2021
11, 2021 — As the rollout of the COVID-19 vaccines continues, scores of questions are emerging. The COVID-19 vaccines work by teaching the immune system to protect against the virus, experts said. Neither of the two vaccines approved in the United States — made by Pfizer-BioNTech and Moderna — contains the live virus.
Vaccine 52
52 
Negative COVID-19 Test to Be Required for People Flying to U.S.
The Pharma Data
JANUARY 13, 2021
13, 2021 — People flying to the United States will soon need to show proof of a negative COVID-19 test result, the U.S. Centers for Disease Control and Prevention said Tuesday. It is likely that the recently identified version of the virus from the United Kingdom is “probably in every state or most states.
Virus 52
52 
AstraZeneca and European Commission reach settlement agreement over vaccine supply,
The Pharma Data
SEPTEMBER 5, 2021
Under the agreement, AstraZeneca commits to deliver 60 million doses of the vaccine by the end of the third quarter 2021, 75 million by the end of the fourth quarter 2021 and 65 million by the end of the first quarter 2022. Legal proceedings by the European Commission against AstraZeneca were initiated in Brussels on 21 April 2021.
Vaccine 52
52 
Moderna COVID-19 Vaccine Protection May Last Years, Company Claims
The Pharma Data
JANUARY 8, 2021
8, 2021 — Moderna CEO Stéphane Bancel said the company’s COVID-19 vaccine may prevent infection for years, CBS News reported Thursday. Centers for Disease Control and Prevention says that because reinfection is possible with COVID-19, even people who have already had the virus should still receive the vaccine.
Vaccine 52
52 
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
The Pharma Data
JANUARY 31, 2021
Clover plans to initiate a global phase 2/3 trial in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.
U.S. COVID-19 Vaccine Rollout Nears 1 Million Doses Per Day
The Pharma Data
JANUARY 14, 2021
14, 2021 — One month after the United States began what has become a troubled rollout of a national COVID-19 vaccination campaign, the effort is finally gathering real steam. Centers for Disease Control and Prevention reported Wednesday. © 2021 HealthDay. Posted: January 2021. Professional. THURSDAY, Jan.
Vaccine 52
52 
Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study
The Pharma Data
AUGUST 16, 2021
During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
The Pharma Data
JANUARY 31, 2021
Clover plans to initiate a global Phase 2/3 efficacy trial of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. EMERYVILLE, Calif. and CHENGDU, China , Feb.
Vaccine 52
52 
mRNA vaccines slash risk of COVID-19 infection by 91% in fully vaccinated people
The Pharma Data
JULY 8, 2021
People who receive mRNA COVID-19 vaccines are up to 91 percent less likely to develop the disease than those who are unvaccinated, according to a new nationwide study of eight sites, including Salt Lake City. 13, 2020 and April 10, 2021. Detection of the virus was reduced by 70% percent among those with breakthrough infections, from 8.9
Vaccine 52
52 
Two billion doses of AstraZeneca’s COVID-19 vaccine supplied to countries across the world
The Pharma Data
NOVEMBER 17, 2021
It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. Data on File Number: REF-131228, 10 November, 2021. Available at: [link] [Accessed August 2021] 6.
Vaccine 52
52 
AHA News: What Heart and Stroke Patients Should Know About COVID-19 Vaccines
The Pharma Data
JANUARY 15, 2021
15, 2021 (American Heart Association News) — Experts have a simple answer for heart and stroke patients questioning whether they need a COVID-19 vaccination. That’s what we want to happen in order for our bodies to make antibodies that will prevent us from getting sick if we encounter the virus again.” FRIDAY, Jan.
Vaccine 52
52 
CureVac provides update on Phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV
The Pharma Data
JUNE 25, 2021
In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. 37, first identified in Peru (21%) and B.1.621,
Vaccine 52
52 
ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
The Pharma Data
JANUARY 4, 2021
Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target. 05, 2021 (GLOBE NEWSWIRE) — ViGeneron GmbH , a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. MUNICH, Germany, Jan.
Therapies 52
52 
Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease in PREVENT-19 Phase 3 trial
The Pharma Data
JUNE 25, 2021
Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% 100) against moderate or severe disease. Efficacy endpoints were accrued from January 25 through April 30, 2021 — a time when the Alpha (B.1.1.7)
Vaccine 40
40 
BinaxNOW Rapid Antigen Test Has Lower Sensitivity Than RT-PCR
The Pharma Data
JANUARY 20, 2021
20, 2021 — The Abbott BinaxNOW COVID-19 Ag Card (BinaxNOW) rapid antigen test has lower sensitivity than reverse transcription-polymerase chain reaction (RT-PCR) for detecting severe acute respiratory syndrome coronavirus 2 infection, according to research published in the Jan. © 2021 HealthDay. Posted: January 2021.
Virus 52
52 
Some Transmission of SARS-CoV-2 Occurs After Seven, 10 Days
The Pharma Data
JANUARY 5, 2021
5, 2021 — There is some onward transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from household contacts released from quarantine after seven or 10 days, according to research published in the Jan. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. © 2021 HealthDay.
Virus 52
52 
Britain to Try Mix-and-Match COVID-19 Vaccinations
The Pharma Data
JANUARY 4, 2021
4, 2021 — If a second dose of the first COVID-19 vaccine is not available or the maker is not known, then another vaccine may be used, new British guidelines say, The New York Times reported Sunday. © 2021 HealthDay. Posted: January 2021. MONDAY, Jan. The new guidance contradicts those in the United States, where the U.S.
Vaccine 52
52 
Regeneron’s COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
The Pharma Data
OCTOBER 28, 2020
In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.
Virus 40
40 
Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine
The Pharma Data
JUNE 26, 2021
JUNE 22 , 2021. The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. Additional pulmonary diseases are being evaluated in discovery-stage research programs that utilize a proprietary lung delivery platform.
Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
The Pharma Data
JULY 28, 2021
The analysis included 945,941 mRNA participants (778,534 with two doses), 426,272 Vaxzevria participants, conducted between 27 December 2020 and 19 May 2021. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
Vaccine 52
52 
Researchers find potential path to a broadly protective COVID-19 vaccine using T cells
The Pharma Data
JULY 6, 2021
If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. ” You can think of a virus’s structure like the design of a house, explains Nathan. .
Vaccine 52
52 
Thinking impaired in 60% of COVID-19 survivors
The Pharma Data
AUGUST 1, 2021
It is not known whether the impairment, such as forgetfulness and language difficulty, will be progressive, said Gabriel de Erausquin, MD, PhD, a neurologist with the health science center’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases. Presented at the Alzheimer’s Association International Conference, July 29, 2021.
Virus 52
52 
PFIZER AND BIONTECH ANNOUNCE SUBMISSION OF INITIAL DATA TO U.S. FDA TO SUPPORT BOOSTER DOSE OF COVID-19 VACCINE
The Pharma Data
AUGUST 16, 2021
Vaccination is our most effective means of preventing COVID-19 infection – especially severe disease and hospitalization – and its profound impact on protecting lives is indisputable. We continuously strive to stay at least one step ahead of the virus. today announced that they have submitted Phase 1 data to the U.S. In the U.S.,
Vaccine 52
52 
Facebook Posts Big Drivers in Vaccine Resistance, Study Finds
The Pharma Data
JANUARY 8, 2021
8, 2021 — As Americans await their COVID-19 shot, a new study of a different vaccine shows the power of Facebook posts in fueling “anti-vax” resistance to immunization. Centers for Disease Control and Prevention. © 2021 HealthDay. Posted: January 2021. FRIDAY, Jan. It can cause genital warts and cancer.
Vaccine 52
52 
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
The Pharma Data
MARCH 11, 2021
Expected to enroll 415 participants; interim results expected in Q3 2021. The Companies expect interim results from this trial in the third quarter of 2021. the vaccines global business unit of Sanofi, to develop mRNA vaccines for up to five infectious disease pathogens. Shots on goal in the fight against COVID-19.
COVID-19 Vaccine AstraZeneca Recommended for Use in the EU
The Pharma Data
JANUARY 29, 2021
29 January 2021 — AstraZeneca’s COVID-19 vaccine has been recommended for conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. Posted: January 2021. Source: AstraZeneca . Source link.
Vaccine 52
52 
COVID-19 Vaccine AstraZeneca Authorised for Use in the EU
The Pharma Data
JANUARY 29, 2021
29 January 2021 — AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation (CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older. Posted: January 2021. Source: AstraZeneca. Source link.
Vaccine 52
52 
Looking beyond traditional oncogenic pathways to break cancer resistance
Drug Target Review
SEPTEMBER 25, 2024
Notably, TT125-802 stabilised disease and prevented further outgrowth of tumours resistant to standard-of-care treatment. Several patients have experienced disease stabilisation, and one NSCLC patient showed a confirmed partial response. 2021 Oct 11 [cited 2024 Sep 4];13(20):5081. 2021 Apr [cited 2024 Sep 4];2(4):377–91.
Small Molecule 105
105 
I’ve Already Had COVID-19, Do I Need the Vaccine?
The Pharma Data
JANUARY 14, 2021
14, 2021 — Folks who’ve gotten through a COVID-19 infection might naturally question whether they need to get a coronavirus vaccination when their turn comes. Twenty-five COVID patients were involved in the study, including nine with severe or moderate disease that required hospitalization. © 2021 HealthDay. .
Vaccine 52
52 
Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates
The Pharma Data
DECEMBER 3, 2020
Clover intends to initiate a separate pivotal clinical trial of the S-Trimer vaccine candidate in combination with Dynavax’s advanced CpG 1018 adjuvant plus alum in the first half of 2021. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Vaccine 52
52 
Let's personalize your content